SCHEMBL13237374

SCHEMBL13237374

Cc1nnc(Cc2ccc(F)cc2)o1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.54
RAB9A P51151 4/20 0.51
HPGD P15428 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
TP53 P04637 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
POLB P06746 2/20 0.49
TSHR P16473 2/20 0.49
USP2 O75604 1/20 0.49
MAPT P10636 2/20 0.43
THRB P10828 2/20 0.43
ALOX12 P18054 1/20 0.43
KMT2A Q03164 1/20 0.43
PTGER1 P34995 1/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
GPR55 Q9Y2T6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31043960 0.81 RAB9A (0.49) NPC1RAB9AHPGDSMN1; SMN2L3MBTL1
SCHEMBL12597232 0.81 RAB9A (0.60) NPC1RAB9AHPGDSMN1; SMN2L3MBTL1
SCHEMBL10284724 0.81 SMO (0.46) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL602528 0.78 HPGD (0.55) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL4191953 0.77 KMT2A (0.40) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL13218158 0.77 NPSR1 (0.55) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL16020967 0.76 MTNR1A (0.42) POLBTSHRUSP2PTGER1MTNR1A
SCHEMBL19224717 0.75 NPC1 (0.51) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL16020925 0.74 HPGD (0.44) NPC1RAB9AHPGDSMN1; SMN2TP53
SCHEMBL14005990 0.74 TSHR (0.44) HPGDL3MBTL1POLBTSHRALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2774928-B1 POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE-INHIBITING ACTIVITY SHIONOGI & CO (JP) 2017-08-30 EP disclosed
US-9200009-B2 Polycyclic pyridone derivative having integrase inhibitory activity SHIONOGI & CO., LTD. (JP) 2015-12-01 US disclosed
US-20140256937-A1 POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
US-20100204237-A1 Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase MIKAMIYAMA HIDENORI 2010-08-12 US disclosed
US-7745453-B2 Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2010-06-29 US disclosed
US-20070149556-A1 Hydroxypyrimidinone derivatives having inhibitory activity against hiv integrase SHIONOGI & CO., LTD. (JP) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149556-A1 Hydroxypyrimidinone derivatives having inhibitory activity against hiv integrase HAT1, SULT1A1, CDK20 NPC1 1851/4885RAB9A 2719/4885HPGD 844/4885
US-20100204237-A1 Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase HAT1, SULT1A1, CDK20 NPC1 1851/4885RAB9A 2719/4885HPGD 844/4885
US-20140256937-A1 POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY TYMP, CDK6, IMPA1 NPC1 3577/4885RAB9A 4533/4885HPGD 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.